Welcome to our dedicated page for hik news (Ticker: hik), a resource for investors and traders seeking the latest updates and insights on hik stock.
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) is a renowned multinational pharmaceutical company headquartered in the UK. With over 45 years of experience in creating high-quality medicines, Hikma is committed to making its products accessible to millions of people worldwide. The company operates across North America, the Middle East, North Africa (MENA), and Europe, using its expertise to transform cutting-edge science into practical solutions that enhance people's lives.
Hikma's recent partnership with Guardant Health, a leading precision oncology company, aims to promote Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring, and tumor mutation profiling across the MENA region. This collaboration will improve access to next-generation sequencing (NGS) tests in the region, where cancer cases are expected to double by 2040.
In February 2024, Hikma launched COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US, providing a new, opioid-free option for adult pain management. Approved by the US FDA, COMBOGESIC® IV offers superior pain relief compared to acetaminophen IV and ibuprofen IV alone, making it a valuable addition to Hikma's expanding portfolio of critical medicines.
Hikma is also deeply involved in combating the opioid overdose epidemic in the US. The Columbus, Ohio facility welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy, to discuss expanding access to Hikma's overdose reversal medicine KLOXXADO® (naloxone HCl) nasal spray 8 mg. This initiative underscores Hikma's commitment to making life-saving medicines like naloxone widely accessible.
Overall, Hikma continues to be a leader in the pharmaceutical industry, dedicated to improving treatment outcomes and advancing precision medicine. The company’s extensive portfolio includes branded and non-branded generic medicines, biologics, immunotherapy, and innovative health technologies, making significant contributions to global health.
Hikma Pharmaceuticals has announced an exclusive six-year commercial partnership with Emergent BioSolutions for the sale of KLOXXADO® (naloxone HCl nasal spray 8 mg) in the U.S. and Canada. KLOXXADO® received FDA approval in April 2021 for emergency treatment of suspected opioid overdose in adults and pediatric patients.
Under the agreement, Emergent will incorporate KLOXXADO® into its naloxone product portfolio and handle all North American sales and marketing. Hikma will continue manufacturing the 8 mg naloxone HCl nasal spray at its Columbus, Ohio facility as the exclusive supplier to Emergent. The partnership combines Hikma's manufacturing capabilities with Emergent's established commercial expertise in naloxone nasal spray distribution.
Hikma will maintain production and marketing of its other naloxone products, including injectable vials and prefilled syringes, ensuring wide accessibility to healthcare providers and the public health community.
Hikma Pharmaceuticals participated in a naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day. The event, held at Groves High School in Savannah, Georgia, marks Hikma's milestone of donating over 600,000 doses of naloxone in the past three years. Hikma is working with government officials and the White House Office of National Drug Control Policy to expand access to naloxone, a vital tool for reversing overdoses.
Hikma manufactures multiple forms of naloxone, including generic injectable vials, prefilled syringes, and KLOXXADO® (naloxone 8mg) intranasal spray. The company's Hikma Community Health initiative partners with frontline organizations to expand naloxone access through donations, partnerships, and awareness programs. Hikma also provides a Co-Pay Assistance Program for KLOXXADO® to increase accessibility and reduce out-of-pocket costs.
Hikma Pharmaceuticals PLC announces the shelf-life extension of KLOXXADO® (naloxone HCl) nasal spray 8mg from 24 to 36 months. This change applies to products manufactured from March 2024 onwards. KLOXXADO® contains twice the naloxone dose of Narcan® Nasal Spray 4mg, offering a important treatment option for opioid overdose reversal.
The extended shelf-life is particularly beneficial for frontline responders and individuals carrying KLOXXADO® for emergency use. This development comes as organizations like the CDC and American Medical Association note that higher doses of naloxone may be necessary to counteract poisoning from illicit fentanyl and other synthetic opioids. Hikma emphasizes its role in combating the opioid crisis, especially as International Overdose Awareness Day approaches on August 31st.
Hikma Pharmaceuticals announced a $15 million investment from its venture capital arm, Hikma Ventures, in Activ Surgical, enhancing the Series B financing to a total of $60 million. Activ Surgical is developing AI-driven surgical technologies aimed at improving surgical outcomes. The ActivSight imaging module, which enhances visualization during surgery, has received FDA clearance and is set for broader availability in 2022. This investment will facilitate Activ Surgical's global launch, empowering surgeons with advanced decision-making tools and improving patient safety.
FAQ
What is Hikma Pharmaceuticals?
Where is Hikma Pharmaceuticals headquartered?
What recent partnership has Hikma entered into?
What is COMBOGESIC® IV?
What steps is Hikma taking to combat the opioid crisis?
How does the partnership with Guardant Health benefit the MENA region?
What are the capabilities of Hikma's KLOXXADO® nasal spray?
What is the duration of the COMBOGESIC® IV treatment?
How does Hikma contribute to global health?
What is the focus of Hikma's venture capital arm?
